+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Anesthetic Effect - Pipeline Review, H1 2020

  • ID: 5017398
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 97 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Avecho Biotechnology Ltd
  • Biotts SA
  • Cuda Pharmaceuticals LLC
  • Lannett Co Inc
  • MedinCell SA
  • Paion AG
  • MORE
Anesthetic Effect - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H1 2020, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.

Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anesthetic Effect (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 6, 1, 4, 1, 12, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Avecho Biotechnology Ltd
  • Biotts SA
  • Cuda Pharmaceuticals LLC
  • Lannett Co Inc
  • MedinCell SA
  • Paion AG
  • MORE
  • Introduction
  • Report Coverage
  • Anesthetic Effect - Overview
  • Anesthetic Effect - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Anesthetic Effect - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Anesthetic Effect - Companies Involved in Therapeutics Development
  • Andros Pharmaceuticals Co Ltd
  • Avecho Biotechnology Ltd
  • Baudax Bio Inc
  • Biotts SA
  • Crescita Therapeutics Inc
  • Cuda Pharmaceuticals LLC
  • Drawbridge Pharmaceuticals Pty Ltd
  • Expanesthetics Inc
  • Hangzhou Adamerck Pharmlabs Inc
  • Hefei Cosource Pharmaceutical Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Lannett Co Inc
  • Lee's Pharmaceutical Holdings Ltd
  • LipoSeuticals Inc
  • MedinCell SA
  • NutriBand Inc
  • Paion AG
  • Physica Pharma
  • Sichuan Haisco Pharmaceutical Co Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • SiteOne Therapeutics Inc
  • Sphaera Pharma Pte Ltd
  • Yichang Humanwell Pharmaceutical Co Ltd
  • Anesthetic Effect - Drug Profiles
  • (lidocaine + tetracaine) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • alphaxalone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Aom-0498 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Aom-0765 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • APC-310 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cocaine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cyclopentol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cysteine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EXPS-01 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EXPS-05 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EXPS-09 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fospropofol disodium - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HR-7056 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • HYRPB-21 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KL-100137 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lidocaine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lidocaine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • morphine glucuronide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MTCA-4 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PHY-301 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • propofol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • propofol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • propofol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • remimazolam besylate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ropivacaine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RP-1000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RP-2000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Block NaV1.7 for Local Anesthetic Effect - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit NMDA Receptor for Anaesthesia - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SPR-819 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Anesthetic Effect - Dormant Projects
  • Anesthetic Effect - Discontinued Products
  • Anesthetic Effect - Product Development Milestones
  • Featured News & Press Releases
  • Mar 12, 2020: Acacia Pharma announces brief extension of FDA review period for NDA for BYFAVO
  • Jan 23, 2020: PAION : Mundipharma receives market approval for Anerem (Remimazolam) in general anesthesia in Japan
  • Jan 13, 2020: Lannett announces FDA approval of NDA for branded anesthetic product, Cocaine Hydrochloride nasal solution 4%
  • Dec 30, 2019: Paion announces submission of new drug application for remimazolam by its licensee Hana Pharm in South Korea
  • Nov 20, 2019: Paion announces submission of the marketing authorization application for Remimazolam in procedural sedation to the European Medicines Agency
  • Jul 16, 2019: United States Patent and Trademark Office issues U.S. patent covering an enhanced formulation of Pliaglis
  • Jun 28, 2019: EIB and German specialty pharmaceutical company PAION AG have signed a €20 million loan agreement
  • Jun 11, 2019: Hana Pharm presented clinical trial results of Remimazolam at International Congress of Cardiothoracic and Vascular Anesthesia
  • Jun 10, 2019: FDA accepts filing of NDA for Remimazolam
  • Apr 09, 2019: Cosmo Pharmaceuticals announces submission of Remimazolam NDA to FDA
  • Nov 06, 2018: R-Pharm Group and Paion announce successful completion of remimazolam phase III clinical trial
  • Oct 08, 2018: PAION announces clinical development progress with Remimazolam by its partner Hana Pharm in South Korea
  • Jul 24, 2018: PAION starts EU Phase III trial with remimazolam in general anesthesia
  • May 17, 2018: Paion announces clinical development progress with Remimazolam by its partner R-Pharm in Russia
  • Apr 30, 2018: Recro Pharma Presents Data for Neuromuscular Blocking and Reversal Agents at the AUA 2018 Annual Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Anesthetic Effect, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Anesthetic Effect - Pipeline by Andros Pharmaceuticals Co Ltd, H1 2020
  • Anesthetic Effect - Pipeline by Avecho Biotechnology Ltd, H1 2020
  • Anesthetic Effect - Pipeline by Baudax Bio Inc, H1 2020
  • Anesthetic Effect - Pipeline by Biotts SA, H1 2020
  • Anesthetic Effect - Pipeline by Crescita Therapeutics Inc, H1 2020
  • Anesthetic Effect - Pipeline by Cuda Pharmaceuticals LLC, H1 2020
  • Anesthetic Effect - Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H1 2020
  • Anesthetic Effect - Pipeline by Expanesthetics Inc, H1 2020
  • Anesthetic Effect - Pipeline by Hangzhou Adamerck Pharmlabs Inc, H1 2020
  • Anesthetic Effect - Pipeline by Hefei Cosource Pharmaceutical Inc, H1 2020
  • Anesthetic Effect - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
  • Anesthetic Effect - Pipeline by Lannett Co Inc, H1 2020
  • Anesthetic Effect - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020
  • Anesthetic Effect - Pipeline by LipoSeuticals Inc, H1 2020
  • Anesthetic Effect - Pipeline by MedinCell SA, H1 2020
  • Anesthetic Effect - Pipeline by NutriBand Inc, H1 2020
  • Anesthetic Effect - Pipeline by Paion AG, H1 2020
  • Anesthetic Effect - Pipeline by Physica Pharma, H1 2020
  • Anesthetic Effect - Pipeline by Sichuan Haisco Pharmaceutical Co Ltd, H1 2020
  • Anesthetic Effect - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H1 2020
  • Anesthetic Effect - Pipeline by SiteOne Therapeutics Inc, H1 2020
  • Anesthetic Effect - Pipeline by Sphaera Pharma Pte Ltd, H1 2020
  • Anesthetic Effect - Pipeline by Yichang Humanwell Pharmaceutical Co Ltd, H1 2020
  • Anesthetic Effect - Dormant Projects, H1 2020
  • Anesthetic Effect - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Anesthetic Effect - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Anesthetic Effect, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Targets, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Andros Pharmaceuticals Co Ltd
  • Avecho Biotechnology Ltd
  • Baudax Bio Inc
  • Biotts SA
  • Crescita Therapeutics Inc
  • Cuda Pharmaceuticals LLC
  • Drawbridge Pharmaceuticals Pty Ltd
  • Expanesthetics Inc
  • Hangzhou Adamerck Pharmlabs Inc
  • Hefei Cosource Pharmaceutical Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • Lannett Co Inc
  • Lee's Pharmaceutical Holdings Ltd
  • LipoSeuticals Inc
  • MedinCell SA
  • NutriBand Inc
  • Paion AG
  • Physica Pharma
  • Sichuan Haisco Pharmaceutical Co Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • SiteOne Therapeutics Inc
  • Sphaera Pharma Pte Ltd
  • Yichang Humanwell Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll